Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
about
Advances in the treatment of invasive neonatal candidiasisPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsAn Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased SafetyToxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisCharacterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.Antifungal pharmacokinetics and pharmacodynamicsComparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensPharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisEfficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celNanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potencyTissue penetration of antifungal agents.Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.Amphotericin B use in children: conventional and lipid-based formulations.Current concepts in antifungal pharmacology.Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.Virulence and Experimental Treatment of Trichoderma longibrachiatum, a Fungus Refractory to Treatment.Development of an antifungal denture adhesive film for oral candidiasis utilizing hot melt extrusion technology.Antifungal drugs: predicting clinical efficacy with pharmacodynamics.Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations.Host defense mechanisms in invasive candidiasis originating in the GI tract.Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.
P2860
Q27022585-D669476A-EA30-448A-90C9-06ED7F389D7EQ27025299-3FF1D3EC-3BC6-49AE-A6FF-7467F1314E93Q28554384-29A59141-C3ED-43F6-BF0E-2CB3D7E2DE76Q33409652-CDFDB794-9CA5-48DF-9653-95DFA617C6CAQ33622932-50EEC5EB-0A9E-4880-AD80-694B55C32D73Q34045435-9D2EE8B7-18EB-4E90-A81E-7AB87588B662Q34763371-58CE639D-4342-4BE6-A01D-03A8028DE868Q35091593-50472AF5-B071-4BF8-AAD7-211AA3A4C989Q35663841-01E4C5AB-6DB8-4AE9-82DB-0BF23F71F52AQ35758926-E40C6571-7C6A-4BF7-BF83-7F25AD00C73EQ35973357-3D44EDAB-7D66-46D9-BFC9-50670F2AB0EDQ36276870-6D2F0431-BCE1-4236-8B09-05870A10A07FQ36757621-D837EF5F-86CF-4B5A-856A-8349E2A02A24Q36949553-DB09A07E-72DA-4AC0-8FB5-11A42E689FB0Q37333175-F635424E-F887-4E51-865C-BC9E228BA6ABQ37401889-64B7737C-733B-4743-8CF9-D72526734704Q37544911-87BDBD5A-C44E-4E8E-A4B5-7667BEAD0D6BQ37613070-7625154C-DEFE-4BAB-B6A4-E60E053DF73AQ37684378-1513D744-6A08-42C0-B9A7-C5210149EDC0Q37854727-B4569B57-7DF7-4817-B00C-2FF1F30C7E90Q37908856-D2E06A05-673F-43CC-A36C-D0D78D7866E2Q38937745-66EAB7F7-43CD-492B-BB9F-60698A5C9C03Q39196802-A6D8346D-5987-4741-99B2-D3C90EFFB499Q40247785-94B15B9F-9DBB-4EDE-A192-094F1DEC27F3Q41464018-38925738-555D-4F9D-973B-204B70367B87Q41786957-58AF1631-D302-4242-8A46-B1F30D1EDFC5Q41843810-500FE977-30C6-46AA-A63F-F74B48D1D0DCQ42276006-4D1FD09F-0CD5-4BC6-A4FF-AF6A1AE512EBQ42723597-3C8F5CE6-2A39-4EA0-949A-3AFC5DCA33E3Q46284853-C19F8591-3FCA-435F-A713-5B0829A46337Q46882635-1A80B1C0-3704-408D-94AF-80DB7B9B1423Q52588345-A33566EE-DFD2-476A-95F2-58D3DC2B103CQ55488494-A1052673-72F6-4865-98F5-F0190E81D00F
P2860
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@ast
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@en
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@nl
type
label
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@ast
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@en
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@nl
prefLabel
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@ast
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@en
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@nl
P2093
P2860
P1476
Pharmacokinetic-pharmacodynami ...... in murine candidiasis models.
@en
P2093
P2860
P304
P356
10.1128/AAC.50.2.674-684.2006
P407
P577
2006-02-01T00:00:00Z